Drugs /

cobolimab

Back to Drugs List

Overview

NCI Definition [1]:
A monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-TIM-3 monoclonal antibody TSR-022 binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.

Clinical Trials

View Clinical Trials for cobolimab

Cobolimab has been investigated in 7 clinical trials, of which 7 are open and 0 are closed. Of the trials investigating cobolimab, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open).

EGFR A763_Y764insFQEA, EGFR Codon 719 Missense, and EGFR Exon 19 Deletion are the most frequent biomarker inclusion criteria for cobolimab clinical trials.

Non-small cell lung carcinoma, appendix carcinoma, and bladder carcinoma are the most common diseases being investigated in cobolimab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Cobolimab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating cobolimab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
immunoglobulin g4, anti-(hepatitis a virus cellular receptor 2 (havcr2)) (humanized clone abt2 gamma4-chain), disulfide with humanized clone abt2 kappa-chain, dimer, tsr-022, anti-tim-3 monoclonal antibody tsr-022, anti-tim3 checkpoint inhibitor tsr-022, anti-tim-3 monoclonal antibody tsr-022, anti-tim3 monoclonal antibody tsr-022
Drug Target(s) [2]:
HAVCR2
NCIT ID [1]:
C128627

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.